Atezolizumab versus chemotherapy in advanced or metastatic nsclc with high blood-based tumor mutational burden: primary analysis of bfast cohort c randomized phase 3 trial

HIGHLIGHTS

• who: Solange Peters from the Centre HospitalLausanne University, Lausanne, Switzerland have published the Article: Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial, in the Journal: (JOURNAL) of 22/09/2017
• what: The primary efficacy objective of this single-arm open-label trial was objective response rate (ORR); the primary biomarker objective was the relationship of investigator-assessed (INV) PFS in patients with bTMB of ≥16. The trial met its primary efficacy endpoint but not the primary PFS-related . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.